Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BILR 355 BS + Ritonavir in healthy males
NCT02253914Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2004
- Primary completion
- Dec 2004
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, single-blind trial of BILR 355 in human immunodeficiency virus type 1 infection (HIV-1) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration time curve of BILR 355 in plasma over one dosing interval at steady state, Maximum concentration of BILR 355 in plasma and 3 more. Started Feb 2004; status: completed.
02
Drugs
BILR 355
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02253914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02253914.